Daily Digest

The Valve Wire

Tuesday, May 26, 2026

Executive Summary

Today's headline finding comes from EuroIntervention: a 7,392-patient international registry shows that early haemodynamic valve deterioration after TAVI — a 10 mmHg gradient rise within three months — occurs in roughly 1 in 30 patients and triples the long-term risk of bioprosthetic valve failure. The signal is most pronounced in small valves, valve-in-valve procedures, and patients discharged without anticoagulation, sharpening the durability conversation that the ESC 2025 guidelines explicitly flagged as the central uncertainty in younger TAVI recipients. Elsewhere, a thoughtful NPJ Cardiovascular Health review argues that primary mitral regurgitation must be managed as a lifetime portfolio of surgical and transcatheter options — not a one-shot decision — while the Cedars-Sinai team has opened a head-to-head RCT of transcatheter versus surgical repair for degenerative MR. Markets continue to punish the structural heart majors, with Boston Scientific and Abbott each down more than 30% over six months even as Anteris Technologies more than doubled.

Early HVD after TAVI (3.1% incidence) is independently associated with a 3-fold rise in bioprosthetic valve failure and 2.3-fold rise in stroke at 4 years (EuroIntervention).
Cedars-Sinai launched NCT07605715, a small but rare randomized comparison of transcatheter vs. surgical repair specifically for degenerative MR — a population where surgery remains Class I in both guidelines.
InnovHeart's transseptal SATURN TMVR system is enrolling (NCT06414265), adding another entrant to a TMVR field still searching for a commercially viable design.
P&F's TricValve bicaval system pivotal trial (NCT06458907, n=780) is preparing to launch — a non-orthotopic alternative to TriClip and EVOQUE that the ESC 2025 guidelines did not specifically address.
Boston Scientific (-42.8% over 6 months) and Abbott (-32.0%) continue to underperform despite Wall Street's "strong buy" and "buy" ratings, reflecting macro pressure rather than structural heart fundamentals.

Aortic Valve (TAVR/TAVI)

[NOTABLE] The Trimaille et al. registry in EuroIntervention deserves close reading. Across 16 centers and 7,392 TAVI patients, early haemodynamic valve deterioration — defined by VARC-3 criteria as a ≥10 mmHg gradient rise within three months — was not a benign echocardiographic curiosity. After median 4-year follow-up, patients with early HVD had a subdistribution HR of 3.04 for bioprosthetic valve failure, 3.53 for stage 3 valve dysfunction, and 2.32 for stroke. Findings persisted in propensity-matched analyses.

The predictors are clinically actionable: prosthesis size <26 mm (aOR 1.96), valve-in-valve procedures (aOR 2.76), and the absence of anticoagulation at discharge (aOR 1.64). The signal in small valves and ViV is consistent with the ESC 2025 emphasis on lifetime management — picking the right index valve matters because a small first valve forecloses good second options. The anticoagulation finding is more provocative and will reignite debate around routine post-TAVI antithrombotic strategy, an area the ATLANTIS, GALILEO, and ENVISAGE-TAVI AF trials left unsettled.

What the study does not resolve: whether early HVD reflects subclinical leaflet thrombosis (potentially reversible with anticoagulation), structural valve deterioration (not), or patient-prosthesis mismatch (a different problem entirely). Without protocolized CT for hypoattenuated leaflet thickening, these mechanisms are conflated. The clinical implication is nonetheless clear — an early post-TAVI echo at 30-90 days should be standard, and a rising gradient is not to be ignored.

On the volume front, Allen Hospital in Iowa crossed its 300th TAVR — a reminder that diffusion to mid-volume community centers is accelerating, which raises its own questions about case selection, operator volume, and the ESC's structural requirement for an experienced Heart Team.

Mitral Valve (MitraClip, PASCAL, TMVR)

Tabata's review in NPJ Cardiovascular Health reframes primary MR as a lifetime management problem rather than a single procedural decision. The argument aligns with the ESC 2025 emphasis on integrated planning: the index repair should be designed to preserve future therapeutic options — whether that means leaving anatomy amenable to TEER, planning for redo surgery, or weighing valve-in-ring feasibility. This is conceptually important because the ESC has expanded asymptomatic repair to Class I when ≥3 risk factors are present (AF, SPAP >50 mmHg, LA dilation, ≥moderate TR), pushing more patients into the surgical pathway at younger ages — patients who will, inevitably, need a second intervention decades later.

The critical counterpoint, articulated by Chikwe, Badhwar, and others, is that "lifetime management" arguments can be deployed to justify TEER first in patients who would clearly do better with durable surgical repair. For degenerative MR with favorable anatomy at an experienced center, primary repair with sub-1% mortality and >95% durability at 20 years remains the benchmark — and no transcatheter alternative comes close.

On the device pipeline, InnovHeart's SATURN transseptal TMVR system is enrolling 30 patients (NCT06414265). TMVR remains a graveyard of promising designs — Tendyne's APOLLO trial outcome remains uncertain in the public domain, Intrepid's pivotal continues (NCT03242642), and the SAPIEN M3 program continues to develop. The clinical need is real, particularly for mitral annular calcification where surgery is hazardous, but the bar set by TEER and surgical repair is high.

Tricuspid Valve (TriClip, TTVR)

No new clinical data today, but the regulatory pipeline is notable: P&F Products + Features is preparing to launch a 780-patient pivotal trial of the TricValve bicaval system (NCT06458907), a heterotopic approach that places valves in the SVC and IVC rather than addressing the tricuspid annulus itself. This is conceptually distinct from TriClip (annular repair) and EVOQUE (orthotopic replacement), and the ESC 2025 Class IIa recommendation for transcatheter TV treatment does not specifically endorse bicaval valving. The trial design will be watched carefully — patient selection criteria, control arm, and endpoints will determine whether this becomes a niche tool for patients with prohibitive tricuspid anatomy or a broader competitor.

The CLASP II TR trial (NCT04097145, PASCAL for TR, n=1,270) continues to recruit, providing the eventual head-to-head context for TriClip's TRILUMINATE Pivotal data.

Surgical vs. Transcatheter Comparisons

The Cedars-Sinai team has opened NCT07605715, a 60-patient randomized comparison of transcatheter vs. surgical treatment of degenerative MR. Sample size is modest and the trial will not be definitive, but it is one of the few prospective head-to-heads in primary MR — a space where the COAPT/RESHAPE-HF2 enthusiasm has spilled inappropriately into degenerative disease in some practices. The larger NCT05051033 (PRIMATY) and the European-led NCT05090540 (transcatheter vs. surgery for secondary MR, n=600) will provide the higher-powered data.

On the AS front, NCT05261204 — a 4,000-patient TAVI-vs-SAVR enrollment-by-invitation study — continues to accrue and will, if completed, add real-world signal to complement the DEDICATE and PARTNER 3 / Evolut Low Risk RCTs that drove the ESC's expansion of TAVI to patients ≥70.

Preprint Highlights

Today's bioRxiv preprints (Furukawa on engineered initiator tRNAs and Kamikawa on streptavidin condensate platforms) are basic molecular biology with no near-term valve relevance. We are not covering them substantively, but flag them for completeness — both papers describe orthogonal protein control systems with potential downstream applications in tissue engineering and bioprosthetic leaflet biology many years out.

Device & Technology

The Navitor Japan study (NCT07193888, n=100) is recruiting under Abbott's sponsorship — a regulatory pathway study rather than a clinical comparator. Edwards' ALLIANCE trial for SAPIEN X4 (NCT05172960, n=1,234) is now active-not-recruiting, with results expected to inform the next platform iteration. The X4 platform is positioned as Edwards' direct response to Medtronic's Evolut and the Myval LANDMARK data showing non-inferiority for newer balloon-expandable designs.

Clinical Trial Updates

Aortic:

NCT07605780 — TAVI in Low Risk in the Real World, COMPLETED, n=650, Centro Cardiologico Monzino.
NCT07193888 — Navitor Japan Study, RECRUITING, n=100, Abbott.
NCT07604402 — TAVI Without On-site Cardiac Surgery, NOT YET RECRUITING, n=1,612, University Hospital of Ferrara. This is a contentious design — both guidelines still recommend on-site surgical backup, and the trial will be closely scrutinized.
NCT05261204 — TAVI vs. SAVR, ENROLLING BY INVITATION, n=4,000, Centre Cardiologique du Nord.
NCT05172960 — ALLIANCE SAPIEN X4, ACTIVE NOT RECRUITING, n=1,234, Edwards.
NCT02701283 — [LANDMARK] Evolut Low Risk long-term follow-up, ACTIVE NOT RECRUITING, n=2,223, Medtronic.
NCT07596394 — IRCCS Policlinico San Matteo TAVI Registry, RECRUITING, n=500.

Mitral Repair:

NCT07605715 — Transcatheter vs. Surgical Treatment of Degenerative MR, RECRUITING, n=60, Cedars-Sinai.
NCT04198870 — [LANDMARK] REPAIR-MR, ACTIVE NOT RECRUITING, n=500, Abbott. Key trial for whether MitraClip can challenge surgical repair in primary MR at moderate surgical risk.
NCT05051033 — [LANDMARK] PRIMATY, RECRUITING, n=450.
NCT03706833 — [LANDMARK] COAPT long-term follow-up, ACTIVE NOT RECRUITING, n=1,247.
NCT05090540 — Transcatheter vs. Surgical MV Operation for Secondary MR, ENROLLING BY INVITATION, n=600.

Mitral Replacement:

NCT06414265 — SATURN Transseptal TMVR, RECRUITING, n=30, InnovHeart.
NCT03242642 — Medtronic Intrepid TMVR, RECRUITING, n=1,056.

Tricuspid Repair:

NCT03904147 — [LANDMARK] TRILUMINATE Pivotal, ACTIVE NOT RECRUITING, n=572, Abbott. Foundation for ESC 2025 Class IIa recommendation for transcatheter TV therapy.
NCT04097145 — [LANDMARK] CLASP II TR, RECRUITING, n=1,270, Edwards.

Tricuspid Replacement:

NCT04482062 — [LANDMARK] TRISCEND II, ACTIVE NOT RECRUITING, n=864, Edwards. Drove TTVR Class IIa for symptoms/QoL despite higher bleeding/pacemaker rates.
NCT06458907 — TricValve Bicaval System Pivotal, NOT YET RECRUITING, n=780, P+F Products + Features.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $87.00 (+1.42%); 6-month change +0.29%; range $74.66–$87.89.
Market cap $50.1B; P/E trailing 47.0, forward 25.9; beta 0.87.
Analyst target $97.15 (range $84–$110, 27 analysts); consensus BUY.
Next earnings 2026-07-23 (EPS est $0.74; revenue est $1.70B).
Edwards is the relative winner of the structural heart cohort — essentially flat over six months while peers cratered. Swedbank trimmed its position but consensus remains constructive. The Evoque tricuspid franchise and PASCAL pipeline are central to the bull thesis.

Medtronic (MDT)

Close: $77.89 (-0.90%); 6-month change -24.7%; range $74.40–$104.70.
Market cap $100.0B; P/E trailing 21.8, forward 12.9; beta 0.63.
Analyst target $107.08 (range $84–$121, 26 analysts); consensus BUY.
Next earnings 2026-06-03 (EPS est $1.56; revenue est $9.61B) — the most imminent catalyst in the group.
The Evolut platform retains category leadership in self-expanding TAVR, and Intrepid TMVR remains the most advanced large-pivotal program. The stock's drawdown reflects portfolio breadth more than structural heart concerns.

Abbott (ABT)

Close: $86.41 (-1.14%); 6-month change -32.0%; range $81.97–$128.39.
Market cap $150.5B; P/E trailing 24.2, forward 14.3; beta 0.65.
Analyst target $118.64 (range $92–$143, 25 analysts); consensus BUY.
Next earnings 2026-07-16 (EPS est $1.28; revenue est $12.53B).
MitraClip and TriClip are the franchise crown jewels; REPAIR-MR readout remains the largest single binary catalyst for the structural heart segment.

Boston Scientific (BSX)

Close: $57.78 (unchanged); 6-month change -42.8%; range $52.52–$101.91.
Market cap $85.9B; P/E trailing 24.2, forward 15.4; beta 0.62.
Analyst target $83.47 (range $60–$106, 32 analysts); consensus STRONG BUY.
Next earnings 2026-07-29 (EPS est $0.83; revenue est $5.40B).
Zacks highlighted WATCHMAN as the structural heart growth engine; the ACURATE Neo2 TAVR platform remains a smaller franchise. The 43% drawdown is striking against a strong-buy consensus — disconnect that may resolve at next earnings.

Anteris Technologies (AVR.AX)

Close: A$13.25 (-0.90%); 6-month change +128.1%; range A$5.70–A$13.80.
Market cap A$1.3B; forward P/E -6.08 (pre-revenue); beta 0.59.
Single analyst target A$13.00.
DurAVR THV continues to attract speculative interest. Investors should remember that single-arm feasibility data are not the same as randomized comparisons against SAPIEN or Evolut — the bar for a new TAVR entrant is now extraordinarily high.

Market outlook: The divergence between Edwards (flat) and Boston Scientific / Abbott / Medtronic (all down 25–43%) is not driven by structural heart fundamentals — the underlying franchises continue to grow. Macro pressure, tariff uncertainty, and rotation out of large-cap medtech explain most of the move. The next inflection points are MDT earnings on June 3 and pipeline readouts from REPAIR-MR, CLASP II TR, and any updates from EARLY TAVR follow-up cohorts. Anteris remains a binary story tied to DurAVR clinical progression.

Closing Thought

If there is a single thread tying today's findings together, it is the durability question. Trimaille's early HVD data, Tabata's lifetime-management framework for MR, and the ESC's expanded TAVI age threshold all converge on the same uncomfortable point: we are implanting transcatheter valves in patients who will outlive them, and our tools for predicting which devices fail early remain blunt. The 30 mmHg gradient at three months may be the new vital sign — and the field has not yet decided what to do about it.

← May 22, 2026